Wegovy resultater: separating clinical fact from common expectations

The biggest myth: that Wegovy works at the same pace for everyone

The most common misunderstanding our prescribers hear is that Wegovy delivers quick, consistent weight loss from the first injection. It doesn't. The medicine starts at 0.25 mg, a dose whose job is to let your system adjust, not to produce meaningful fat loss. Most people spend the first eight to twelve weeks stepping through 0.5 mg and 1.0 mg before reaching doses where appetite suppression becomes clinically significant.

That calibration period frustrates many patients, especially those who have read about 15% average weight loss without realising how that figure was reached. In the STEP 1 trial, 68 weeks passed before the primary endpoint was measured. The headline figure reflects the full treatment arc, not the first month. People who stop early because early results feel modest are making a decision based on the wrong part of the curve.

A practical habit worth building: weigh yourself once a week, at the same time of day, on the same scales, and record it. Month-on-month comparison is far more informative than day-to-day fluctuation, and gives your prescriber genuinely useful data at each clinical review. That single habit takes under a minute and removes most of the anxiety that week-to-week scale changes create.

What rigorous evidence says about Wegovy results

The STEP 1 trial randomised 1,961 adults with obesity (BMI 30 or above) or overweight (BMI 27 or above with at least one weight-related condition) to semaglutide 2.4 mg or placebo over 68 weeks. Average weight loss in the semaglutide group was 14.9% (reported broadly as 15%) compared with 2.4% in the placebo group. Around one third of participants on semaglutide lost 20% or more of their body weight; around half lost at least 15%.

Those figures are striking, but they sit alongside an important footnote: participants also followed a reduced-calorie diet and increased physical activity throughout the trial. The medicine works as part of a combined approach, not instead of one. If you want a closer look at how those trial results translate to real-world outcomes, that page goes through the data in more detail.

The MHRA also approved a higher 7.2 mg maintenance dose in January 2026, with trial data showing approximately 20.7% average weight loss over 72 weeks, narrowing the gap with tirzepatide results. That dose option is worth discussing with a prescriber if the standard maintenance dose has been maximally tolerated without reaching the weight-management goals set at assessment.

How results change across the dosing schedule

Understanding the titration schedule explains a lot about why results feel slow at first. The standard Wegovy pathway moves from 0.25 mg through 0.5 mg, 1.0 mg and 1.7 mg before reaching the 2.4 mg maintenance dose, with roughly four weeks at each level. That means most people are not on their maintenance dose until around week 16 to 20. Meaningful, sustained appetite suppression (the mechanism behind the weight loss) is largely a feature of the maintenance phase, not the escalation period.

For people wondering about the very early weeks, what happens in the first week on Wegovy is mostly about tolerability and the first small physiological shifts, with visible scale movement typically coming later. By week six, most people have stepped up at least once and often begin to see appetite changes becoming more pronounced. Patients curious about what Wegovy delivers by the two-week mark will find that early changes are still modest, reflecting where the dose sits on the titration ladder at that point. The question of how long Wegovy takes to work in a meaningful clinical sense is best answered as: allow the full titration arc before drawing conclusions.

The NICE appraisal of semaglutide (TA875) recommends considering stopping the medicine if less than 5% weight loss has been achieved after six months on the maintenance dose, a clinical checkpoint worth discussing with your prescriber rather than acting on independently.

Context that changes how results should be read

Trial populations are not the same as everyone who might be prescribed Wegovy in private practice. STEP 1 excluded people with type 2 diabetes, active heart failure, and certain other conditions, which means results in broader clinical populations can differ. Lifestyle factors (how consistently someone follows dietary guidance, their baseline activity level, whether they have conditions affecting metabolism) all influence individual outcomes.

Cost is sometimes raised as a proxy for effectiveness: some people assume the most expensive option produces the best results. The honest picture is more nuanced. Understanding what Wegovy actually costs in the UK is a useful step before starting, because private treatment requires sustained investment, and the medicine works best when not interrupted for financial reasons. If you are exploring weight-loss treatment options more broadly, a prescriber can compare the evidence base for different medicines in your specific situation rather than applying population averages.

Wegovy is a prescription-only medicine. The clinical assessment that comes before any prescription exists precisely because the trial averages do not predict your individual result, the prescriber's job is to use what they know about you to make that judgement. Speak to our prescribers if you would like that conversation to start.